Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $709,750.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the sale, the executive vice president now directly owns 580,325 shares in the company, valued at approximately $16,475,426.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, September 23rd, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00.
• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The stock was sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Trading Up 12.9 %

EXEL traded up $3.71 on Wednesday, hitting $32.44. 6,737,999 shares of the company were exchanged, compared to its average volume of 2,047,408. The firm has a 50-day moving average price of $26.81 and a two-hundred day moving average price of $24.15. The company has a market cap of $9.25 billion, a price-to-earnings ratio of 27.97, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $33.32.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Equities analysts expect that Exelixis, Inc. will post 1.58 EPS for the current year.

Analysts Set New Price Targets

EXEL has been the topic of a number of research reports. Stephens increased their price objective on Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a report on Wednesday. The Goldman Sachs Group upgraded shares of Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. Piper Sandler increased their price objective on shares of Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Morgan Stanley boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $31.44.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. LSV Asset Management lifted its position in Exelixis by 1,651.4% in the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after acquiring an additional 2,616,278 shares during the last quarter. Hsbc Holdings PLC boosted its position in shares of Exelixis by 45.3% in the 2nd quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock valued at $2,031,000 after purchasing an additional 28,126 shares during the period. Farallon Capital Management LLC grew its stake in Exelixis by 1.6% during the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after buying an additional 424,000 shares during the last quarter. Intech Investment Management LLC increased its position in Exelixis by 155.8% during the first quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock worth $2,374,000 after buying an additional 60,925 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Exelixis in the first quarter valued at approximately $1,281,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.